---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-24-000199"
form_type: "8-K"
ticker: "AXIM"
cik: "0001514946"
company_name: "AXIM BIOTECHNOLOGIES, INC."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:22:01.715303+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AXIM Biotechnologies settles IMS litigation; to issue 20M restricted shares plus cash and royalties

## Summary
- Settlement with Innovative Medical Supplies resolves two lawsuits; no admission of wrongdoing.
- Cash payment of $100,000 payable over 24 months.
- Royalty of $0.35 per dry eye test cassette sold, capped at $475,000 total.
- Issues 20M restricted shares; 12-month lock-up, then drip-out limit of 1% of outstanding per 90 days.
- Shares issued under Section 4(a)(2) of Securities Act; unregistered sale.

## SEC filing metadata
- accession: 0001096906-24-000199
- form_type: 8-K
- ticker: AXIM
- cik: 0001514946
- company_name: AXIM BIOTECHNOLOGIES, INC.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514946/000109690624000199/0001096906-24-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514946/000109690624000199/axim-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-24-000199
- JSON: https://secwatch.observer/filing/0001096906-24-000199.json
- Plain text: https://secwatch.observer/filing/0001096906-24-000199.txt

## Key facts
- Material Agreements
  AXIM BIOTECHNOLOGIES, INC. entered into Settlement Agreement with Innovative Medical Supplies, LLC (effective 2024-02-07).
  - Action: entry
  - Agreement: settlement
  - Counterparty: Innovative Medical Supplies, LLC
  - Effective: 2024-02-07
  source text: Effective February 7, 2024, the Company entered into a confidential Global Settlement Agreement and Mutual Release (the “Settlement Agreement”) to resolve the IMS Action as well as a second related action involving many of the same parties.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690624000199/0001096906-24-000199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.